Catalog No.
EVV14301
Expression system
Mammalian Cells
Species
Severe acute respiratory syndrome coronavirus (SARS-CoV)
Protein length
Met1-Lys1193
Predicted molecular weight
137.09 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P59594
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Nucleoprotein, Nucleocapsid protein, Protein N, NP, NC
RBD Amplicon Sequencing and Evolutionary Analysis of SARS-CoV-2 Variants from Wastewater Samples., PMID:40515922
Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates., PMID:40498855
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720
Long COVID-19 autoantibodies and their potential effect on fertility., PMID:40496870
SARS-CoV-2 exploits steroidogenic machinery, triggers lipid metabolism for viral replication and induces immune response in Leydig cells of K18-hACE2 mice., PMID:40496014
Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry., PMID:40483334
Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2., PMID:40481111
Deletion of the Envelope gene attenuates SARS-CoV-2 infection by altered Spike localization and increased cell-to-cell transmission., PMID:40475451
No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations., PMID:40473598
Serum Levels of IL-21 and IL-27 Do not Reflect differential Avidity of Anti-SARS-CoV-2 IgG Antibodies in Symptomatic and Asymptomatic COVID-19 Patients., PMID:40471646
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern., PMID:40463385
Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study., PMID:40462400
SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023., PMID:40462062
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response., PMID:40461490
Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations., PMID:40458889
Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 'Patria' vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version., PMID:40458417
Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis., PMID:40456237
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections., PMID:40447072
Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota., PMID:40444030
ACE2, a therapeutic target of COVID-19, needs to be treated with caution., PMID:40439840
Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection., PMID:40437072
Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929
A Novel Antiviral Therapeutic Platform: Anchoring IFN-β to the Surface of Infectious Virions Equips Interferon-Evasive Virions with Potent Antiviral Activity., PMID:40431708
Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants., PMID:40431702
Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652
SARS-CoV-2 Spike Protein and Long COVID-Part 2: Understanding the Impact of Spike Protein and Cellular Receptor Interactions on the Pathophysiology of Long COVID Syndrome., PMID:40431631
SARS-CoV-2 Spike Protein and Long COVID-Part 1: Impact of Spike Protein in Pathophysiological Mechanisms of Long COVID Syndrome., PMID:40431629
The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil., PMID:40430765
Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies., PMID:40430736
Efficient Searches in Protein Sequence Space Through AI-Driven Iterative Learning., PMID:40429882
Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen., PMID:40429644
Host susceptibilities and entry processes of SARS-CoV-2 Omicron variants using pseudotyped viruses carrying spike protein., PMID:40426227
Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate., PMID:40425664
Using Machine Learning to Analyze Molecular Dynamics Simulations of Biomolecules., PMID:40423571
Is SARS-CoV-2 Spike Evolution Being Retargeted at the N-Terminal Domain?, PMID:40415355
Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant., PMID:40413500
Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model., PMID:40410742
Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains., PMID:40408899
T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine., PMID:40407705
Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster., PMID:40406109
Food-derived bioactive pigment phycocyanobilin binds to SARS-CoV-2 spike protein both covalently and noncovalently affecting its conformation and functionality., PMID:40404003
Construction of a variable fragment (Fv)-immunoglobulin A (IgA) anti-receptor binding domain (RBD) SARS-CoV-2 library based on IgA from Indonesian COVID-19 survivors., PMID:40403817
Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies., PMID:40403696
Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles., PMID:40402246
Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination., PMID:40386778
Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants., PMID:40383030
A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses., PMID:40379714
For research use only. Not for human or drug use.
